Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasIndolent LymphomasMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)TransplantationDiseaseAcute Lymphoblastic LeukaemiaAcute Myeloid LeukemiaChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaChronic Myeloid LeukemiaMyelodysplastic NeoplasmsNHL, B-Cell Type, Follicular Grade I-IIIaStem Cell Transplantation, AllogeneicSubgroupICD10C82.9C91.0-C91.1-C92.0-C92.1-C92.5-C92.6-C92.7-C92.8-C92.9-C93.0-D46.-MeSHHematopoietic Stem Cell TransplantationLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteLymphoma, FollicularMyelodysplastic SyndromesPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaTransplantation ConditioningSequenceChemotherapyChemo-substanceAzacitidineCyclophosphamideFludarabineLenalidomideChemo-substanceAzacitidineCyclophosphamideFludarabineLenalidomideChemo-substanceAzacitidineCyclophosphamideFludarabineLenalidomideChemo-substanceAzacitidineCyclophosphamideFludarabineLenalidomideNo. Substances12 RadiotherapySupportive therapySupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiclosporin ACiprofloxacinCotrimoxazoleCyclophosphamideDexamethasoneDimetindenEtoposide phosphateFluconazoleFludarabineFosaprepitantFurosemideGranisetronLetermovirLevetiracetamMelphalanMesnaMethotrexateMethylprednisoloneMycophenolate mofetilParacetamolPosaconazolePrednisoloneRituximabSirolimusTacrolimusThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiclosporin ACiprofloxacinCotrimoxazoleCyclophosphamideDexamethasoneDimetindenEtoposide phosphateFluconazoleFludarabineFosaprepitantFurosemideGranisetronLetermovirLevetiracetamMelphalanMesnaMethotrexateMethylprednisoloneMycophenolate mofetilParacetamolPosaconazolePrednisoloneRituximabSirolimusTacrolimusThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiclosporin ACiprofloxacinCotrimoxazoleCyclophosphamideDexamethasoneDimetindenEtoposide phosphateFluconazoleFludarabineFosaprepitantFurosemideGranisetronLetermovirLevetiracetamMelphalanMesnaMethotrexateMethylprednisoloneMycophenolate mofetilParacetamolPosaconazolePrednisoloneRituximabSirolimusTacrolimusThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiclosporin ACiprofloxacinCotrimoxazoleCyclophosphamideDexamethasoneDimetindenEtoposide phosphateFluconazoleFludarabineFosaprepitantFurosemideGranisetronLetermovirLevetiracetamMelphalanMesnaMethotrexateMethylprednisoloneMycophenolate mofetilParacetamolPosaconazolePrednisoloneRituximabSirolimusTacrolimusThiotepaTreosulfanUrsodeoxycholic acidValaciclovirNo. Substances391011121314151617Protocol classificationTherapy classificationalternativecurrent standardIntensityhigh doseKonditionierung, intensitäts- oder dosisreduziert (RIC)Konditionierung, myeloablativ (MAC)Konditionierung, nicht-myeloablativ (NMA)Standard doseTherapy indicationRelapse therapyTherapy phaseallogene StammzelltransplantationTherapy intentioncurativecurative or palliativepalliativeRisksBleedingCardiotoxicityEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHepatotoxicityHyperbilirubinemiaInfectionsNeurotoxicityNeutropeniaPainPneumoniaRenal FailureSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorBeelen DWBlume KGBolaños-Meade JCiurea SOCraddock CCutler CDi Bartolomeo PDusenbery KEEstey EKhouri IFKröger NLee JHLuznik LLübbert MMarks RPlatzbecker URambaldi ASchroeder TShimoni ASolomon SRSora FStölzel FDiseaseAML, 40-65 Jahre, ECOG 0-2, < 5% BlastenAML, haploidentische StammzelltransplantationAML, haploidentische StammzelltransplantationAML, MDS, CML, NHL, ungeeignet für konventionelle intensive KonditionierungAML, über 50 J.AML- oder CMML-Rezidiv nach allogener StammzelltranplantationAML- oder MDS-Rezidiv nach allogener StammzelltranplantationAML/ALL/CML, allogene StammzelltransplantationAML/ALL/MDS, allogene SCTAML/MDS, 15-70 Jahre, mit HLA-identischem oder an einem Locus nicht übereinstimmender Geschwister-, Familien- oder nicht verwandtem SpenderAML/MDS, 18-65 Jahre, < 5% BlastenAML/MDS, 18-70 Jahre, AML in kompletter hämatologischer Remission (unter 5% Blasten) oder MDS (unter 20% Blasten), HCT-CI Score über 2AML/MDS, allogene StammzelltransplantationAML/MDS, ungeeignet für konventionelle intensive KonditionierungAML/MDS, unter 55 JahreCLL, FL Grad I-IIIa, vor allogener SZTDrohendes AML- oder MDS-Rezidiv nach allogener Stammzelltranplantation (Spenderchimärismus <80%)GvHD ProphylaxeGvHD Prophylaxe bei allogener SZTHämatologische Erkrankung (AML, PNH, CML, Multiples Myelom), allogene SZTOriginAlbert-Ludwigs University Medical Center, Freiburg, GermanyAsan Medical Center, University of Ulsan College of Medicine, SeoulCarl Gustav Carus Technical University of Dresden, Dresden, Germany, RELAZA trialCity of Hope National Medical Center, California, USADana-Farber Cancer Institute, Harvard Medical School, Boston, MADepartment of Haematology and Oncology, Albert-Ludwigs University Medical Center, FreiburgDepartment of Hematology, Bone Marrow Transplant Center, Spirito Santo Hospital, Pescara, ItalyDepartment of Therapeutic Radiology, University of Minnesota Hospital and Clinics, MinneapolisDivision Hematology and Oncology, University of Freiburg Medical Center, Freiburg, GermanyHematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, ItalyIstituto di Ematologia, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, ItalyOncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, GermanySidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USASidney Kimmel Comprehensive Cancer Center at Johns Hopkins UniversityThe Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GeorgiaThe Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, IsraelThe University of Texas M. D. Anderson Cancer Center, Houston, USAUniversity Hospital Schleswig-Holstein, Kiel, Christian Albrechts University, Kiel, GermanyUniversity Medical Center Hamburg-Eppendorf, HamburgUniversity of Birmingham, Birmingham, United KingdomUniversity of Texas M. D. Anderson Cancer Center, Houston, USAUniversity of Texas MD Anderson Cancer Center, Houston, USAWest German Cancer Centre, University of Duisburg-Essen, Essen, GermanyProtokolle in Überarbeitung 23 protocols foundAnti-thymocyte Globulin (Rabbit) 10 / Cyclosporine 3 / Methotrexate (15/10), allo-SCT, GvHD prophylaxis (PID3213 V1.0)Azacitidin 100, akute myeloische Leukämie und myelodysplastisches Syndrom nach allogener Stammzelltransplantation (PID2302 V1.0)Azacitidin 100, akute myeloische Leukämie und myelodysplastisches Syndrom nach allogener Stammzelltransplantation, Variante 1 (PID2320 V1.0)Azacitidin 75 / Lenalidomid 25, akute myeloische Leukämie und myelodysplastisches Syndrom nach allogener Stammzelltransplantation (PID827 V1.2)Azacitidin 75, akute myeloische Leukämie und myelodysplastisches Syndrom nach allogener Stammzelltransplantation (PID2327 V1.0)Busulfan 3.2 / Cyclophosphamide 60, Allogeneic Stem Cell Transplantation, MAC (PID882 V1.0)Cyclophosphamide 50 / Tacrolimus 0.02 / Mycophenolate Mofetil 15, allo-SCT, GvHD prophylaxis (PID1739 V1.0)Cyclophosphamid 60 / TBI 13,2, allogene Stammzelltransplantation, MAC (PID3218 V1.0)Etoposidphosphat 60 / TBI 13,2, allogene Stammzelltransplantation, MAC (PID3221 V1.0)Fludarabine 30 / Busulfan 3.2, Acute Myeloid Leukemia, Stem Cell Transplantation, Allogeneic (PID3226 V1.0)Fludarabin 30 / Carmustin 150 / Melphalan 110, allogene Stammzelltransplantation, RIC (PID880 V1.0)Fludarabin 30 / Carmustin 200 / Melphalan 140, akute myeloische Leukämie und myelodysplastisches Syndrom, allogene Stammzelltransplantation, RIC (PID1705 V1.0)Fludarabin 30 / Cyclophosphamid 14,5 / TBI 2, allogene Stammzelltransplantation, RIC (PID1077 V1.0)Fludarabin 30 / Melphalan 100, akute myeloische Leukämie und myelodysplastisches Syndrom, allogene Stammzelltransplantation, RIC (PID3225 V1.0)Fludarabin 30 / TBI 12, allogene Stammzelltransplantation, MAC (PID3219 V1.0)Fludarabin 30 / Treosulfan 10, akute myeloische Leukämie und myelodysplastisches Syndrom, allogene Stammzelltransplantation, MAC (PID1706 V1.0)Fludarabine 40 / Busulfan 0.8 / Anti-thymocyte Globulin (Rabbit) (0.5/2.0/2.5), Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation, MAC (PID885 V1.0)Fludarabin 40 / Busulfan 3,2 / Antithymozytenglobulin vom Kaninchen 10, akute myeloische Leukämie und myelodysplastisches Syndrom, allogene Stammzelltransplantation, MAC (PID881 V1.0)Melphalan 140 / Thiotepa 10 / Fludarabin 40, akute myeloische Leukämie und myelodysplastisches Syndrom, allogene Stammzelltransplantation, RIC (PID1738 V1.0)Rituximab 375 / Fludarabine 30 / Cyclophosphamide 750, follicular lymphoma, stages I–IIIa, Allogeneic Stem Cell Transplantation, NMA (PID3223 V1.0)Tacrolimus 0.02 / Sirolimus (12/4), allo-SCT, GvHD prophylaxis (PID3229 V1.0)Thiotepa 5 / Busulfan 3,2 / Fludarabin 50, akute myeloische Leukämie, allogene Stammzelltransplantation, MAC (PID3214 V1.0)Thiotepa 5 / Busulfan 3,2 / Fludarabin 50, akute myeloische Leukämie, allogene Stammzelltransplantation, RIC (PID1709 V1.0)
